Armed with the first approval for an FcRn antagonist, the Belgian company’s chief executive remains convinced by a solo strategy.
Kodiak, Biomarin and Argenx prepare for clinical catalysts.
2022 kicks off with key FDA decisions for Roche, Novartis and Pfizer, while Astrazeneca hopes to extend Lynparza even further.
2021 rounds off with key FDA decisions for Argenx, Calliditas and Merck, while Novartis will be hoping for an early Leqvio verdict.
Biogen’s Aduhelm was the big one, but there are plenty of other key regulatory decisions still pending this year.
Immunovant and other FcRn-players must hope that a potential safety signal turns out to be indication rather than class specific.
Bintrafusp alfa’s most important study, head to head against Keytruda in front-line lung cancer, is scrapped.
Blockbuster sales are predicted for several projects nearing approval, from Biogen, Argenx, Fibrogen and others.